Senseonics Holdings, Inc. Common Stock Q4 2024 Earnings Report

Senseonics Holdings, Inc. Common Stock EPS Results

• Actual EPS: -$2.40
• Consensus EPS: -$0.60
• Beat/Miss: Missed by -$1.80
• One Year Ago EPS: -$1.40

Senseonics Holdings, Inc. Common Stock Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Senseonics Holdings, Inc. Common Stock Announcement Details

• Quarter: Q4 2024
• Date: 3/3/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Senseonics Holdings, Inc. is a medical technology company focused on developing and commercializing continuous glucose monitoring (CGM) systems for people with diabetes. Its technology is designed to measure glucose levels continuously and provide readings through a wearable transmitter and mobile application, supporting diabetes management and treatment decisions.

The company’s principal product is the Eversense CGM system, which uses a small sensor implanted under the skin, a removable smart transmitter worn over the sensor, and a smartphone application. Unlike many traditional CGM systems that require frequent sensor replacement, Eversense is designed for long-term use, with available versions supporting sensor wear periods of up to 180 days and, following regulatory authorization, up to one year.

Senseonics was founded in 1996 and is headquartered in Germantown, Maryland. The company serves the U.S. market and has expanded internationally through commercial and distribution relationships, including its partnership with Ascensia Diabetes Care. Senseonics’ systems are intended for people with diabetes who require ongoing glucose monitoring and are distributed in markets where the appropriate regulatory approvals have been obtained.